Q1 Earnings Estimate for Metagenomi Issued By HC Wainwright

Metagenomi, Inc. (NASDAQ:MGX - Free Report) - Investment analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of Metagenomi in a research note issued on Tuesday, May 27th. HC Wainwright analyst M. Kapoor forecasts that the company will post earnings per share of ($0.66) for the quarter. HC Wainwright has a "Buy" rating and a $7.00 price objective on the stock. The consensus estimate for Metagenomi's current full-year earnings is ($2.46) per share. HC Wainwright also issued estimates for Metagenomi's Q2 2026 earnings at ($0.71) EPS, Q3 2026 earnings at ($0.75) EPS and Q4 2026 earnings at ($0.79) EPS.

Metagenomi (NASDAQ:MGX - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.06). Metagenomi had a negative net margin of 134.27% and a negative return on equity of 43.23%. The business had revenue of $4.13 million for the quarter, compared to the consensus estimate of $8.75 million.

Other equities research analysts also recently issued reports about the company. Chardan Capital decreased their price objective on Metagenomi from $13.00 to $12.00 and set a "buy" rating on the stock in a research report on Thursday, May 15th. Wall Street Zen downgraded Metagenomi from a "hold" rating to a "strong sell" rating in a research report on Thursday, May 22nd. Finally, Wells Fargo & Company restated an "overweight" rating and issued a $16.00 price target (down from $20.00) on shares of Metagenomi in a research report on Wednesday, May 14th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. According to MarketBeat, Metagenomi has a consensus rating of "Moderate Buy" and an average price target of $13.00.

Metagenomi Trading Down 5.0%

Shares of NASDAQ:MGX traded down $0.09 during trading on Wednesday, reaching $1.69. The company's stock had a trading volume of 260,689 shares, compared to its average volume of 790,750. The stock has a market capitalization of $63.19 million, a PE ratio of -0.80 and a beta of -0.65. Metagenomi has a 12 month low of $1.23 and a 12 month high of $6.90. The firm's 50 day simple moving average is $1.56 and its two-hundred day simple moving average is $2.24.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the business. AQR Capital Management LLC bought a new stake in shares of Metagenomi during the 1st quarter worth approximately $119,000. Nuveen LLC bought a new position in Metagenomi in the 1st quarter valued at $86,000. Virtu Financial LLC purchased a new stake in Metagenomi in the first quarter worth $43,000. Bank of New York Mellon Corp lifted its position in shares of Metagenomi by 39.6% during the first quarter. Bank of New York Mellon Corp now owns 50,387 shares of the company's stock worth $69,000 after purchasing an additional 14,296 shares during the last quarter. Finally, Pinnacle Wealth Planning Services Inc. purchased a new stake in shares of Metagenomi during the fourth quarter valued at $92,000.

Metagenomi Company Profile

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.